Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label, single arm, phase II trial

Yasuhiro Oki*, Michael S. Ewer, Daniel J. Lenihan, Michael J. Fisch, Fredrick B. Hagemeister, Michelle Fanale, Jorge Romaguera, Barbara Pro, Nathan Fowler, Anas Younes, Alan B. Astrow, Xuelin Huang, Larry W. Kwak, Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Michael Wang, Luis E. Fayad, Jean Bernard Durand, M. Alma Rodriguez

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label, single arm, phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences